Patent ID: 8859498
Filing Date: 2014-10-14
Classification: A61K,A61P,C07K,C12N,C12Y

Abstract:
1. A targeted therapeutic comprising: a lysosomal enzyme; and a lysosomal targeting domain sufficiently duplicative of human IGF-II such that the lysosomal targeting domain binds the human cation-independent mannose-6-phosphate receptor in a mannose-6-phosphate-independent manner, wherein the lysosomal targeting domain comprises a variant of human IGF-II having an amino acid sequence at least 70% identical to mature human IGF-II (SEQ ID NO:8), wherein the variant of human IGF-II has diminished binding affinity for the IGF-I receptor relative to the affinity of naturally-occurring human IGF-II for the IGF-I receptor, and wherein the lysosomal targeting domain and the lysosomal enzyme are crosslinked to each other using a chemical crosslinking agent.